ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J. Souers, Steven W. Elmore, Brian D. Dayton et al.|Nature Medicine|2013Cited by 3k
Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208Andrew J. Souers, Steven W. Elmore, Erwin R. Boghaert et al.|Unknown|2013Cited by 182
The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents <i>In Vitro</i> and <i>In Vivo</i>Jun Chen, Steven W. Elmore, Sha Jin et al.|Molecular Cancer Therapeutics|2011Cited by 149